Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2006

01-12-2006

A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey

Authors: Şerif Yılmaz, Kadim Bayan, Yekta Tüzün, Sabri Batun, Abdullah Altıntaş

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2006

Login to get access

Abstract

Background

Possible association of inflammatory bowel disease (IBD) with the most common inherited prothrombotic conditions has been the focus of many investigations. Advance in modern molecular biology is expanding the thrombophilia evaluation steadily. We tried to put forward a comprehensive thrombophilic profile in IBD and to see the probable role of this profile in pathogenesis.

Methods

A total of 60 adults (33 patients and 27 healthy controls) were included. We used the CVD-StripAssay which is based on the reverse-hybridization principle to identify a total of 12 thrombophilic gene mutations: Factor V R506Q, Factor V H1299R, prothrombin G20210A, Factor XIII V34L, beta-Fibrinogen-455 G-A, PAI-1 4G/5G, platelet GPIIIa L33P, MTHFR C677T, MTHFR A1298C, ACE I/D, Apo B R3500Q and Apo E2/E3/E4, respectively. Besides, we evaluated many related blood parameters such as protein C, protein S, AT-III, IL-6, TNF-alpha, Apo-A1, Apo-B100, homocysteine (tHcy) etc. using commercially available assays.

Results

The frequencies of genetic polymorphisms were found to be statistically insignificant among patients and controls, except for three: Beta-Fibrinogen-455G-A, MTHFR A1298C and ACE-I/D. Two patients with a history of deep venous thrombosis had more than one polymorphism. Patients with MTHFR C677T and MTHFR A1298C gene mutations had a similar mean tHcy levels with controls. Patients with Apolipoprotein B R3500Q and Apolipoprotein E4 gene mutations had similar mean LDL-cholesterol levels. Mean total cholesterol and triglyceride levels were similar in patients and controls of Apo E2, E3, E4 alleles.

Conclusion

Predominantly, the presence of genetic mutations that predispose to hypercoagulable states does not appear to be in correlation with IBD. There was a statistical difference between the proportions of the mutated allele frequencies of Beta-Fibrinogen-455G-A, MTHFR A1298C and ACE-I/D in IBD.
Literature
1.
go back to reference Bernstein CN, Blanchard JF, Houston D et al (2001) The incidence of venous thromboembolic disease among patients with IBD: a population-based study. Thromb Haemost 85:430–434PubMed Bernstein CN, Blanchard JF, Houston D et al (2001) The incidence of venous thromboembolic disease among patients with IBD: a population-based study. Thromb Haemost 85:430–434PubMed
2.
go back to reference Talbot RW, Heppell J, Dozois RR et al (1986) Vascular complications of inflammatory bowel disease. Mayo Clin Proc 61:140–145PubMed Talbot RW, Heppell J, Dozois RR et al (1986) Vascular complications of inflammatory bowel disease. Mayo Clin Proc 61:140–145PubMed
3.
go back to reference Dhillon AP, Anthony A, Sim R et al (1992) Mucosal capillary thrombi in rectal biopsies. Histopathology 21:127–133PubMed Dhillon AP, Anthony A, Sim R et al (1992) Mucosal capillary thrombi in rectal biopsies. Histopathology 21:127–133PubMed
4.
go back to reference Wakefield AJ, Sawyer AM, Hudson M et al (1991) Smoking, the oral contraceptive pill and Crohn’s disease. Dig Dis Sci 36:1147–1150CrossRefPubMed Wakefield AJ, Sawyer AM, Hudson M et al (1991) Smoking, the oral contraceptive pill and Crohn’s disease. Dig Dis Sci 36:1147–1150CrossRefPubMed
5.
go back to reference Logan RFA, Kay CR (1989) Oral contraception, smoking and inflammatory bowel disease findings in the Royal College of General Practitioners oral contraceptive study. Int J Epidemiol 18:105–107PubMed Logan RFA, Kay CR (1989) Oral contraception, smoking and inflammatory bowel disease findings in the Royal College of General Practitioners oral contraceptive study. Int J Epidemiol 18:105–107PubMed
6.
go back to reference Thompson N, Wakefield AJ, Pounder RE (1995) Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 108:1011–1015CrossRefPubMed Thompson N, Wakefield AJ, Pounder RE (1995) Inherited disorders of coagulation appear to protect against inflammatory bowel disease. Gastroenterology 108:1011–1015CrossRefPubMed
7.
go back to reference Crowther MA, Kelton JG (2003) Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 138(2):128–134PubMed Crowther MA, Kelton JG (2003) Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 138(2):128–134PubMed
8.
go back to reference Martinelli I (2001) Risk factors in venous thromboembolism. Thromb Haemost 86(1):395–403PubMed Martinelli I (2001) Risk factors in venous thromboembolism. Thromb Haemost 86(1):395–403PubMed
10.
go back to reference Truelove S, Witts L (1955) Cortisone in ulcerative colitis. Br Med J 2:1041–1048 Truelove S, Witts L (1955) Cortisone in ulcerative colitis. Br Med J 2:1041–1048
11.
go back to reference Kirsner JB, Spencer JA (1963) Family occurrences of ulcerative colitis, regional enteritis, and ileocolitis. Ann Intern Med 59:133–144PubMed Kirsner JB, Spencer JA (1963) Family occurrences of ulcerative colitis, regional enteritis, and ileocolitis. Ann Intern Med 59:133–144PubMed
12.
go back to reference Papa A, Danese S, Grillo A et al (2003) Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 98(6):1247–1251CrossRefPubMed Papa A, Danese S, Grillo A et al (2003) Review article: inherited thrombophilia in inflammatory bowel disease. Am J Gastroenterol 98(6):1247–1251CrossRefPubMed
13.
go back to reference Wakefield AJ, Sawyerr AM, Dhillon AP et al (1989) Pathogenesis of Crohn’s disease: multifocal gastrointestinal infarction. Lancet 2(8671):1057–1062CrossRefPubMed Wakefield AJ, Sawyerr AM, Dhillon AP et al (1989) Pathogenesis of Crohn’s disease: multifocal gastrointestinal infarction. Lancet 2(8671):1057–1062CrossRefPubMed
14.
go back to reference Jackson LM, O’Gorman PJ, O’Connell J et al (1997) Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 90(3):183–188CrossRefPubMed Jackson LM, O’Gorman PJ, O’Connell J et al (1997) Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. QJM 90(3):183–188CrossRefPubMed
15.
go back to reference Donmez Y, Kanadasi M, Tanriverdi K et al (2004) Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 45(3):505–512CrossRefPubMed Donmez Y, Kanadasi M, Tanriverdi K et al (2004) Prothrombin 20210GA and factor V Leiden mutations in patients less than 55 years old with myocardial infarction. Jpn Heart J 45(3):505–512CrossRefPubMed
16.
go back to reference Castoldi E, Rosing J. Factor V (2004) Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 11(3):176–181CrossRefPubMed Castoldi E, Rosing J. Factor V (2004) Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 11(3):176–181CrossRefPubMed
17.
go back to reference Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593–1596CrossRefPubMed Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593–1596CrossRefPubMed
18.
go back to reference Rosendaal FR, Koster T, Vandenbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 86:4700–4702 Rosendaal FR, Koster T, Vandenbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 86:4700–4702
19.
go back to reference Haslam N, Standen GR, Probert GS (1999) An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 11:1289–1291CrossRefPubMed Haslam N, Standen GR, Probert GS (1999) An investigation of the association of the factor V Leiden mutation and inflammatory bowel disease. Eur J Gastroenterol Hepatol 11:1289–1291CrossRefPubMed
20.
go back to reference Over HH, Ulgen S, Tuglular T et al (1998) Thrombophilia and inflammatory bowel disease: Does factor V mutation have a role? Eur J Gastroenterol Hepatol 10:827–829PubMedCrossRef Over HH, Ulgen S, Tuglular T et al (1998) Thrombophilia and inflammatory bowel disease: Does factor V mutation have a role? Eur J Gastroenterol Hepatol 10:827–829PubMedCrossRef
21.
go back to reference Haslam N, Standen GR, Probert CS (2001) An investigation of the association of the prothrombin G20210A gene mutation and inflammatory bowel disease: Factor II and IBD. Inflamm Bowel Dis 7:133–135CrossRefPubMed Haslam N, Standen GR, Probert CS (2001) An investigation of the association of the prothrombin G20210A gene mutation and inflammatory bowel disease: Factor II and IBD. Inflamm Bowel Dis 7:133–135CrossRefPubMed
22.
go back to reference Papa A, Stefano V, Gasbarrini A et al (2000) Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 11:499–503CrossRefPubMed Papa A, Stefano V, Gasbarrini A et al (2000) Prevalence of factor V Leiden and the G20210A prothrombin-gene mutation in inflammatory bowel disease. Blood Coagul Fibrinolysis 11:499–503CrossRefPubMed
23.
go back to reference Bernardi F, Faioni EM, Castoldi E et al (1997) A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 90:1552–1557PubMed Bernardi F, Faioni EM, Castoldi E et al (1997) A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 90:1552–1557PubMed
24.
go back to reference Mikkola H, Syrjala M, Rasi V et al (1994) Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 84(2):517–525PubMed Mikkola H, Syrjala M, Rasi V et al (1994) Deficiency in the A-subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 84(2):517–525PubMed
25.
go back to reference Saibeni S, Vecchi M, Faioni EM et al (2003) Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. Dig Liver Dis 35(1):32–36CrossRefPubMed Saibeni S, Vecchi M, Faioni EM et al (2003) Val34Leu factor XIII polymorphism in Italian patients with inflammatory bowel disease. Dig Liver Dis 35(1):32–36CrossRefPubMed
26.
go back to reference Dong QL, Zhang C (2004) Association between the polymorphism of beta-fibrinogen gene-455G/A and ischemic stroke. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21(3):274–276PubMed Dong QL, Zhang C (2004) Association between the polymorphism of beta-fibrinogen gene-455G/A and ischemic stroke. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 21(3):274–276PubMed
27.
go back to reference Humphries S, Henry J, Montgomery H (1999) Gene–environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrinolysis 10:S17–S21PubMed Humphries S, Henry J, Montgomery H (1999) Gene–environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. Blood Coagul Fibrinolysis 10:S17–S21PubMed
28.
go back to reference Eriksson P, Kallin B, Van’t Hooft FM et al (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851–1855CrossRefPubMed Eriksson P, Kallin B, Van’t Hooft FM et al (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851–1855CrossRefPubMed
29.
go back to reference Tassies D, Espinosa G, Munoz-Rodriguez FJ et al (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43: 2349–2358CrossRefPubMed Tassies D, Espinosa G, Munoz-Rodriguez FJ et al (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43: 2349–2358CrossRefPubMed
30.
go back to reference Stegnar M, Uhrin P, Peternel P et al (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79: 975–979PubMed Stegnar M, Uhrin P, Peternel P et al (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79: 975–979PubMed
31.
go back to reference Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081–1086CrossRefPubMed Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081–1086CrossRefPubMed
32.
go back to reference Segui R, Estelles A, Mira Y et al (2000) PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111(1):122–128CrossRefPubMed Segui R, Estelles A, Mira Y et al (2000) PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111(1):122–128CrossRefPubMed
33.
go back to reference Hefler L, Jirecek S, Heim K et al (2004) Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. J Soc Gynecol Investig 11(1):42–44CrossRefPubMed Hefler L, Jirecek S, Heim K et al (2004) Genetic polymorphisms associated with thrombophilia and vascular disease in women with unexplained late intrauterine fetal death: a multicenter study. J Soc Gynecol Investig 11(1):42–44CrossRefPubMed
34.
go back to reference Sans M, Tassies D, Pellise M et al (2003) The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn’s disease. Aliment Pharmacol Ther 17(8):1039–1047CrossRefPubMed Sans M, Tassies D, Pellise M et al (2003) The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn’s disease. Aliment Pharmacol Ther 17(8):1039–1047CrossRefPubMed
35.
go back to reference Slowik A, Dziedzic T, Turaj W et al (2004) A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke 35(7):1589–1593CrossRefPubMed Slowik A, Dziedzic T, Turaj W et al (2004) A2 alelle of GpIIIa gene is a risk factor for stroke caused by large-vessel disease in males. Stroke 35(7):1589–1593CrossRefPubMed
36.
go back to reference den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759–762CrossRef den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759–762CrossRef
37.
go back to reference Morgenstern I, Raimakers MTM, Peters WHM et al (2003) Homocysteine, cysteine and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci 48:2083–2090CrossRefPubMed Morgenstern I, Raimakers MTM, Peters WHM et al (2003) Homocysteine, cysteine and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci 48:2083–2090CrossRefPubMed
38.
go back to reference van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neuraltube defects? Am J Hum Genet 62:1044–1051CrossRefPubMed van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neuraltube defects? Am J Hum Genet 62:1044–1051CrossRefPubMed
39.
go back to reference Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169–172CrossRefPubMed Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169–172CrossRefPubMed
40.
go back to reference Hanson NQ, Aras O, Yang F et al (2001) C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 47(4):661–666PubMed Hanson NQ, Aras O, Yang F et al (2001) C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 47(4):661–666PubMed
41.
go back to reference Oldenburg B, Fijnheer R, van der Griend R et al (2000) Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 95(10):2825–2830CrossRefPubMed Oldenburg B, Fijnheer R, van der Griend R et al (2000) Homocysteine in inflammatory bowel disease: a risk factor for thromboembolic complications? Am J Gastroenterol 95(10):2825–2830CrossRefPubMed
42.
go back to reference Brown NJ, Vaughan DE (2000) Prothrombotic effects of angiotensin. Adv Intern Med 45:419–429PubMed Brown NJ, Vaughan DE (2000) Prothrombotic effects of angiotensin. Adv Intern Med 45:419–429PubMed
43.
go back to reference Rigat B, Hubert C, Alhenc-Gelas MF et al (1990) An insertion/deletion polymorphism in the angiotensin converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343–1346PubMedCrossRef Rigat B, Hubert C, Alhenc-Gelas MF et al (1990) An insertion/deletion polymorphism in the angiotensin converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343–1346PubMedCrossRef
44.
go back to reference Butler R, Morris AD, Burchell B et al (1999) DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension 33:1164–1168PubMed Butler R, Morris AD, Burchell B et al (1999) DD angiotensin-converting enzyme gene polymorphism is associated with endothelial dysfunction in normal humans. Hypertension 33:1164–1168PubMed
45.
go back to reference Bedir A, Arik N, Adam B et al (1999) Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension. Am J Hypertens 12:1038–1043CrossRefPubMed Bedir A, Arik N, Adam B et al (1999) Angiotensin converting enzyme gene polymorphism and activity in Turkish patients with essential hypertension. Am J Hypertens 12:1038–1043CrossRefPubMed
46.
go back to reference Brown MS, Goldsteın JL (1986) A receptor mediated pathway for cholesterol homeostasis. Science 232:34–47CrossRefPubMed Brown MS, Goldsteın JL (1986) A receptor mediated pathway for cholesterol homeostasis. Science 232:34–47CrossRefPubMed
47.
go back to reference Tybjaerg-Hansen A, Steffensen R, Meinertz H et al (1998) Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 338:1577–1584CrossRefPubMed Tybjaerg-Hansen A, Steffensen R, Meinertz H et al (1998) Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. N Engl J Med 338:1577–1584CrossRefPubMed
48.
go back to reference Miller J (1990) Dyslipoproteinaemia of liver disease. Bailliers Clin Endocrinol Metab 4:807–832CrossRef Miller J (1990) Dyslipoproteinaemia of liver disease. Bailliers Clin Endocrinol Metab 4:807–832CrossRef
49.
go back to reference Belo L, Gaffney D, Caslake M et al (2004) Apolipoprotein E and cholesteryl ester transfer protein polymorphisms in normal and preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 112(1):9–15CrossRefPubMed Belo L, Gaffney D, Caslake M et al (2004) Apolipoprotein E and cholesteryl ester transfer protein polymorphisms in normal and preeclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 112(1):9–15CrossRefPubMed
50.
go back to reference Scuteri A, Bos AJ, Zonderman AB et al (2001) Is the apoE4 allele an independent predictor of coronary events? Am J Med 110(1):28–32CrossRefPubMed Scuteri A, Bos AJ, Zonderman AB et al (2001) Is the apoE4 allele an independent predictor of coronary events? Am J Med 110(1):28–32CrossRefPubMed
Metadata
Title
A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey
Authors
Şerif Yılmaz
Kadim Bayan
Yekta Tüzün
Sabri Batun
Abdullah Altıntaş
Publication date
01-12-2006
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2006
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-006-9032-5

Other articles of this Issue 3/2006

Journal of Thrombosis and Thrombolysis 3/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.